Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes.

[1]  G. Garcia-Manero.  CME Information: Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification and management , 2014 .

[2]  C. Bloomfield,et al.  New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461 , 2013, Genes, chromosomes & cancer.

[3]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[4]  Michael Heuser,et al.  Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. , 2012, Blood.

[5]  A. Jankowska,et al.  Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. , 2012, Blood.

[6]  Rizk E. Khidre,et al.  Regioselective synthesis and antimicrobial activities of some novel aryloxyacetic acid derivatives. , 2012, European journal of medicinal chemistry.

[7]  A. Jankowska,et al.  SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts , 2012, Leukemia.

[8]  Xiao Li,et al.  The role of histone methyltransferase EZH2 in myelodysplastic syndromes , 2012, Expert review of hematology.

[9]  M. Stratton,et al.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.

[10]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[11]  L. Medeiros,et al.  Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia. , 2011, American journal of clinical pathology.

[12]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[13]  M. McDevitt,et al.  Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. , 2011, Blood.

[14]  Benjamin L Ebert,et al.  Unraveling the molecular pathophysiology of myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Drexler,et al.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.

[16]  R. Kuiper,et al.  Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.

[17]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[18]  A. Jankowska,et al.  Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome‐wide single nucleotide polymorphism array analysis , 2010, Genes, chromosomes & cancer.

[19]  C. O'keefe,et al.  Application of array‐based whole genome scanning technologies as a cytogenetic tool in haematological malignancies , 2009, British journal of haematology.

[20]  Jungwon Huh,et al.  Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. , 2009, Blood.

[21]  M. McDevitt,et al.  P035 Improvement in cytogenetic diagnosis and clinical prognostication using SNP-A karyotyping in combination with metaphase cytogenetics in MDS, MDS/MPD and secondary AML , 2009 .

[22]  B. Woda,et al.  Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. , 2008, Cancer.

[23]  S. Fröhling,et al.  Chromosomal abnormalities in cancer. , 2008, The New England journal of medicine.

[24]  K. Döhner,et al.  Molecular characterization of acute myeloid leukemia , 2008, Haematologica.

[25]  C. O'keefe,et al.  Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. , 2008, Blood.

[26]  C. O'keefe,et al.  Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes , 2007, Leukemia.

[27]  M. Andersen,et al.  Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. , 2007, Hematology. American Society of Hematology. Education Program.

[28]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[29]  C. Bloomfield,et al.  A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies , 2006, Leukemia.

[30]  T. Leblanc,et al.  DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification , 2005, Leukemia.

[31]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[32]  A. Hagemeijer,et al.  Rare recurring balanced chromosome abnormalities in therapy‐related myelodysplastic syndromes and acute leukemia: Report from an International Workshop † , 2002, Genes, chromosomes & cancer.

[33]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[34]  B. Bain,et al.  Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study , 1995, British journal of haematology.

[35]  J. Rowley,et al.  The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. , 1994, Blood.

[36]  A. Raza,et al.  Translocation t(6;9)(p22.3;q34) in myelodysplastic syndrome--refractory anemia with excess blasts. , 1987, Cancer genetics and cytogenetics.